Historically, Contract Research Organization (CROs) were employed by their customers to carry out certain pre-designated tasks. However, CROs evolved to provide solutions to customer’s challenges and now are evolving further to provide innovation
in the form of project ideas. Collaborative partnerships on integrated drug discovery projects are now common in the drug discovery landscape.
In this webinar, Eurofins Discovery, an integrated drug discovery provider, will present case histories of handling complex integrated drug discovery projects, including delivery of preclinical candidates from challenging start points. Learn how
industry-leading pharma and biotech companies are using CROs to get their drugs to market faster.
- Understand the basics of integrated drug discovery and how to make it work for your company
- How to evaluate different medicinal chemistry outsourcing models to best fit your needs
- Learn how medicinal chemistry experience is important for successful drug candidate delivery with a case study on bRo5 and macrocyclic compounds, including molecular chameleons
Vicky Steadman, PhD,
Integrated Drug Discovery Business Line Leader
Vicky Steadman carried out a PhD and post-doc in total synthesis of macrocyclic natural products at Cambridge University with Prof Ian Paterson and at U Penn with Prof Amos B. Smith, III. Her industrial career initiated at Merck (Terling’s
Park) working on neuroscience targets. She then moved to GlaxoSmithKline (Harlow) focussing on anti-infectives and anti-inflammatories. Upon joining Selcia in 2008, she rose from Senior Scientist to Director of Discovery. Upon Selcia’s
acquisition by Eurofins in 2017, she has taken on a global role as Business Line Leader of Integrated Drug Discovery Services at Eurofins Discovery. Vicky has a strong track record in innovative medicinal chemistry, and has delivered multiple
pre-clinical candidates for customers. She is named on around 30 papers and patents and is a Fellow of the Royal Society of Chemistry.
Cost: No Cost!